<!DOCTYPE html>
<html>
<head>
<title>Karvea, INN - irbesartan</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge">
</head>
<body>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:274pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">ANNEX I </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:175pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">SUMMARY OF PRODUCT CHARACTERISTICS </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 75 mg tablets. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each tablet contains 75 mg of irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipient with known effect: 15.37 mg of lactose monohydrate per tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2771 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">engraved on the other side. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea is indicated in adults for the treatment of essential hypertension. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea at a dose of 150 mg once daily generally provides a better 24-hour blood pressure control than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialyzed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients and in the elderly over 75 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect with Karvea (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special Populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(75 mg) should be considered for patients undergoing haemodialysis (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical experience in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Older people</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">age, dosage adjustment is not usually necessary for the older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">made. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of Administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For oral use. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Second and third trimesters of pregnancy (see sections 4.4 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Intravascular volume depletion: symptomatic hypotension, especially after the first dose, may occur in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment and kidney transplantation: when Karvea is used in patients with impaired renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">experience regarding the administration of Karvea in patients with a recent kidney transplantation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypertensive patients with type 2 diabetes and renal disease: the effects of irbesartan both on renal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with patients with advanced renal disease. In particular, they appeared less favourable in women and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-white subjects (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS): </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blockade therapy is considered absolutely necessary, this should only occur under specialist </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium in patients at risk is recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium: the combination of lithium and Karvea is not recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophic cardiomyopathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Primary aldosteronism: patients with primary aldosteronism generally will not respond to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therefore, the use of Karvea is not recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General: in patients whose vascular tone and renal function depend predominantly on the activity of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">underlying renal disease, including renal artery stenosis), treatment with angiotensin</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">converting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ischaemic cardiovascular disease could result in a myocardial infarction or stroke. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">possibly because of higher prevalence of low-renin states in the black hypertensive population (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">changed to alternative antihypertensive treatments which have an established safety profile for use in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16 years old but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the current data are insufficient to support an extension of the use in children until further data become </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available (see sections 4.8, 5.1 and 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipients: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 75 mg tablet contains lactose. Patients with rare hereditary problems of galactose intolerance, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">total lactase deficiency or glucose-galactose malabsorption should not take this medicine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 75 mg tablet contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tablet, that is to say essentially &#x2018;sodium-free&#x2019;. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diuretics and other antihypertensive agents: other antihypertensive agents may increase the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of irbesartan; however Karvea has been safely administered with other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotension when initiating therapy with Karvea (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aliskiren-containing products or ACE-inhibitors: clinical trial data has shown that dual blockade of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Potassium supplements and potassium-sparing diuretics:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based on experience with the use of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is, therefore, not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reversible increases in serum lithium concentrations and toxicity have been reported during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended.</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may occur. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased risk of worsening of renal function, including possible acute renal failure, and an increase in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium, especially in patients with poor pre-existing renal function. The combination should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be administered with caution, especially in the elderly. Patients should be adequately hydrated and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">consideration should be given to monitoring renal function after initiation of concomitant therapy, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">periodically thereafter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Repaglinide: irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan increased the C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.3-fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">during the first trimester of pregnancy has not been conclusive; however a small increase in risk </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive treatments which have an established safety profile for use in pregnancy. When </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alternative therapy should be started. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Exposure to AIIRA therapy during the second and third trimesters is known to induce human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal function and skull is recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.3 and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended and alternative treatments with better established safety profiles during breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are preferable, especially while nursing a newborn or preterm infant. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is unknown whether irbesartan or its metabolites are excreted in human milk.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolites in milk (for details see 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the first signs of parental toxicity (see section 5.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">machine. When driving vehicles or operating machines, it should be taken into account that dizziness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or weariness may occur during treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose range), gender, age, race, or duration of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following table presents the adverse drug reactions that were reported in placebo-controlled trials </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chronic renal insufficiency and overt proteinuria and in excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The frequency of adverse reactions listed below is defined using the following convention: </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">7 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">very common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/10); </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/100 to &lt; 1/10)</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">; uncommon (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/1,000 to &lt; 1/100); rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are presented in order of decreasing seriousness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adverse reactions additionally reported from post&#x2013;marketing experience are also listed. These adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions are derived from spontaneous reports. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blood and lymphatic system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaemia, thrombocytopenia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immune system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaphylactic shock</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism and nutrition disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia, hypoglycaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nervous system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness, orthostatic dizziness* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vertigo, headache </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ear and labyrinth disorder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tinnitus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cardiac disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tachycardia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vascular disorders</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">orthostatic hypotension* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">flushing</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Respiratory, thoracic and mediastinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal disorders</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nausea/vomiting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea, dyspepsia/heartburn </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dysgeusia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatobiliary disorders</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">jaundice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis, abnormal liver function</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skin and subcutaneous tissue disorders</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">leukocytoclastic vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Musculoskeletal and connective tissue disorders</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">musculoskeletal pain* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthralgia, myalgia (in some cases associated with increased plasma creatine kinase  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">levels), muscle cramps </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal and urinary disorders</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> impaired renal function including cases of renal failure in patients at risk (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reproductive system and breast disorders</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sexual dysfunction </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General disorders and administration site conditions</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chest pain</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Investigations</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with placebo. In diabetic hypertensive patients with microalbuminuria and normal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal function, hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 29.4% of the patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients with chronic renal insufficiency and overt proteinuria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 26.3% of the patients in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significant increases in plasma creatine kinase were commonly observed (1.7%) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan treated subjects. None of these increases were associated with identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical musculoskeletal events. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In 1.7% of hypertensive patients with advanced diabetic renal disease treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">child recipients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in Appendix V.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">also occur from overdose. No specific information is available on the treatment of overdose with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea. The patient should be closely monitored, and the treatment should be symptomatic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: Angiotensin-II antagonists, plain. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ATC code: C09C A04. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) antagonist. It is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected to block all actions of angiotensin-II mediated by the AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> receptor, regardless of the source </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) receptors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:295pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">9 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolic activation for its activity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose-related for once-a-day doses with a tendency towards plateau at doses above 300 mg. Doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses. Once daily dosing with 150 mg produced trough and mean 24-hour responses similar to twice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily dosing on the same total dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension has not been observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trough of 7-10/3-6 mm Hg (systolic/diastolic). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products that affect the renin-angiotensin system, black hypertensive patients have notably less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that of white patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no clinically important effect on serum uric acid or urinary uric acid secretion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension) children and adolescents aged 6 to 16 years over a three-week period. At the end of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose). No significant difference was apparent between these doses. Adjusted mean change of trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose), 5.6 mmHg (high dose). Over a subsequent two-week period where patients were re-randomized </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan (see section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension and type 2 diabetes with renal disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The &#x201c;Irbesartan Diabetic Nephropathy Trial (IDNT)&#x201d; shows that irbesartan decreases the progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,715 hypertensive patients with type </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 diabetes, proteinuria &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 900 mg/day and serum creatinine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality was observed, while a positive trend in the reduction in ESRD and a significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduction in doubling of serum creatinine were observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subgroups which represented 32% and 26% of the overall study population respectively, a renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">benefit was not evident, although the confidence intervals do not exclude it. As for the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the overall population, although an increased incidence of non-fatal MI was seen for women and a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">failure was reduced in the overall population. However, no proper explanation for these findings in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">women has been identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The study of the &#x201c;Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diabetes Mellitus (IRMA 2)&#x201d; shows that irbesartan 300 mg delays progression to overt proteinuria in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(serum creatinine </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure goal was &#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg. Additional antihypertensive agents (excluding ACE </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improvement in the glomerular filtration rate (GFR) was not observed during the first three months of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment. The slowing in the progression to clinical proteinuria was evident as early as three months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and continued over the 2-years period. Regression to normoalbuminuria (&lt; 30 mg/day) was more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequent in the Karvea 300 mg group (34%) than in the placebo group (21%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to monotherapy was observed. Given their similar pharmacodynamic properties, these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">11 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease, cardiovascular disease, or both. The study was terminated early because of an increased risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren group than in the placebo group and adverse events and serious adverse events of interest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group than in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absorption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Distribution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The volume of distribution is 53-93 litres.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biotransformation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following oral or intravenous administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, 80-85% of the circulating plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(approximately 6%). </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> studies indicate that irbesartan is primarily oxidised by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Linearity / non-linearity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are attained at 1.5-2 hours after oral administration. The total body and renal clearance are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">157-176 and 3-3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11-15 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients. However, there was no difference in the half-life and accumulation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were also somewhat greater in older subjects </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years) than those of young subjects (18-40 years). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">However the terminal half-life was not significantly altered. No dosage adjustment is necessary in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elimination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, about 20% of the radioactivity is recovered in the urine, and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(twelve children over 12 years, nine children between 6 and 12 years). Results showed that C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, AUC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatic impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significantly altered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies have not been performed in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3</span></b><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical safety studies, high doses of irbesartan (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 250 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mg/kg/day in rats and &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 100 mg/kg/day in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At very high doses (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 500 mg/kg/day) degenerative changes in the kidney (such as interstitial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 90 mg/kg/day, in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 mg/kg/day). All of these changes were considered to be caused by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of mutagenicity, clastogenicity or carcinogenicity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility and reproductive performance were not affected in studies of male and female rats even at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is excreted in the milk of lactating rats. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abortion or early resorption were noted at doses causing significant maternal toxicity, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality. No teratogenic effects were observed in the rat or rabbit. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Microcrystalline cellulose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Croscarmellose sodium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lactose monohydrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium stearate </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">13 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Colloidal hydrated silica </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregelatinized maize starch </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Poloxamer 188 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Do not store above 30&#xb0;C. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 14 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 28 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 98 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 x 1 tablet in PVC/PVDC/Aluminium perforated unit dose blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sanofi Winthrop Industrie </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">82 avenue Raspail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">94250 Gentilly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">France </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/001-003 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/010 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/013 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 27 August 1997 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of latest renewal: 27 August 2007 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency http://www.ema.europa.eu </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">14 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 150 mg tablets. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each tablet contains 150 mg of irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipient with known effect: 30.75 mg of lactose monohydrate per tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2772 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">engraved on the other side. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea is indicated in adults for the treatment of essential hypertension. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea at a dose of 150 mg once daily generally provides a better 24-hour blood pressure control than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialyzed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients and in the elderly over 75 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect with Karvea (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special Populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(75 mg) should be considered for patients undergoing haemodialysis (see section 4.4). </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">15 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical experience in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Older people</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">age, dosage adjustment is not usually necessary for older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">made. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of Administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For oral use. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Second and third trimesters of pregnancy (see sections 4.4 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Intravascular volume depletion: symptomatic hypotension, especially after the first dose, may occur in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment and kidney transplantation: when Karvea is used in patients with impaired renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">experience regarding the administration of Karvea in patients with a recent kidney transplantation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypertensive patients with type 2 diabetes and renal disease: the effects of irbesartan both on renal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with patients with advanced renal disease. In particular, they appeared less favourable in women and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-white subjects (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS): there is evidence that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual blockade therapy is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered absolutely necessary, this should only occur under specialist supervision and subject to </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">16 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blockers should not be used concomitantly in patients with diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium in patients at risk is recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium: the combination of lithium and Karvea is not recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophic cardiomyopathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Primary aldosteronism: patients with primary aldosteronism generally will not respond to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therefore, the use of Karvea is not recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General: in patients whose vascular tone and renal function depend predominantly on the activity of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">underlying renal disease, including renal artery stenosis), treatment with angiotensin</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">converting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ischaemic cardiovascular disease could result in a myocardial infarction or stroke. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">possibly because of higher prevalence of low-renin states in the black hypertensive population (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">changed to alternative antihypertensive treatments which have an established safety profile for use in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16 years old but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the current data are insufficient to support an extension of the use in children until further data become </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available (see sections 4.8, 5.1 and 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipients: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 150 mg tablet contains lactose. Patients with rare hereditary problems of galactose intolerance, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">total lactase deficiency or glucose-galactose malabsorption should not take this medicine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 150 mg tablet contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tablet, that is to say essentially &#x2018;sodium-free&#x2019;. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diuretics and other antihypertensive agents: other antihypertensive agents may increase the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of irbesartan; however Karvea has been safely administered with other </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">17 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotension when initiating therapy with Karvea (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aliskiren-containing products and ACE-inhibitors:.clinical trial data has shown that dual blockade of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Potassium supplements and potassium-sparing diuretics:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based on experience with the use of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is, therefore, not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reversible increases in serum lithium concentrations and toxicity have been reported during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended.</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may occur. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased risk of worsening of renal function, including possible acute renal failure, and an increase in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium, especially in patients with poor pre-existing renal function. The combination should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be administered with caution, especially in the elderly. Patients should be adequately hydrated and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">consideration should be given to monitoring renal function after initiation of concomitant therapy, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">periodically thereafter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Repaglinide: irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan increased the C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.3-fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">during the first trimester of pregnancy has not been conclusive; however a small increase in risk </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive treatments which have an established safety profile for use in pregnancy. When </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alternative therapy should be started. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Exposure to AIIRA therapy during the second and third trimesters is known to induce human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal function and skull is recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.3 and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended and alternative treatments with better established safety profiles during breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are preferable, especially while nursing a newborn or preterm infant. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is unknown whether irbesartan or its metabolites are excreted in human milk.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolites in milk (for details see 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the first signs of parental toxicity (see section 5.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">machines. When driving vehicles or operating machines, it should be taken into account that dizziness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or weariness may occur during treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose range), gender, age, race, or duration of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following table presents the adverse drug reactions that were reported in placebo-controlled trials </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chronic renal insufficiency and overt proteinuria and in excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The frequency of adverse reactions listed below is defined using the following convention: </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">19 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">very common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/100 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); uncommon (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/1,000 to &lt; 1/100); rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are presented in order of decreasing seriousness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adverse reactions additionally reported from post&#x2013;marketing experience are also listed. These adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions are derived from spontaneous reports. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blood and lymphatic system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaemia, thrombocytopenia  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immune system disorders</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaphylactic shock</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism and nutrition disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia, hypoglycaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nervous system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness, orthostatic dizziness* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vertigo, headache </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ear and labyrinth disorder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tinnitus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cardiac disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tachycardia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vascular disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">orthostatic hypotension* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">flushing</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Respiratory, thoracic and mediastinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nausea/vomiting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea, dyspepsia/heartburn </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dysgeusia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatobiliary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">jaundice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis, abnormal liver function</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skin and subcutaneous tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">leukocytoclastic vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Musculoskeletal and connective tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">musculoskeletal pain* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthralgia, myalgia (in some cases associated with increased plasma creatine kinase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">levels), muscle cramps </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal and urinary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> impaired renal function including cases of renal failure in patients at risk (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reproductive system and breast disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sexual dysfunction </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General disorders and administration site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chest pain</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Investigations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with placebo. In diabetic hypertensive patients with microalbuminuria and normal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal function, hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 29.4% of the patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients with chronic renal insufficiency and overt proteinuria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 26.3% of the patients in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significant increases in plasma creatine kinase were commonly observed (1.7%) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan treated subjects. None of these increases were associated with identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical musculoskeletal events. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In 1.7% of hypertensive patients with advanced diabetic renal disease treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">child recipients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in Appendix V.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">also occur from overdose. No specific information is available on the treatment of overdose with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea. The patient should be closely monitored, and the treatment should be symptomatic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: Angiotensin-II antagonists, plain. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ATC code: C09C A04. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) antagonist. It is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected to block all actions of angiotensin-II mediated by the AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> receptor, regardless of the source </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) receptors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">21 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolic activation for its activity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose-related for once-a-day doses with a tendency towards plateau at doses above 300 mg. Doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses. Once daily dosing with 150 mg produced trough and mean 24-hour responses similar to twice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily dosing on the same total dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension has not been observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trough of 7-10/3-6 mm Hg (systolic/diastolic). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products that affect the renin-angiotensin system, black hypertensive patients have notably less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that of white patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no clinically important effect on serum uric acid or urinary uric acid secretion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension) children and adolescents aged 6 to 16 years over a three-week period. At the end of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose). No significant difference was apparent between these doses. Adjusted mean change of trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose), 5.6 mmHg (high dose). Over a subsequent two-week period where patients were re-randomized </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan (see section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension and type 2 diabetes with renal disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The &#x201c;Irbesartan Diabetic Nephropathy Trial (IDNT)&#x201d; shows that irbesartan decreases the progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,715 hypertensive patients with type </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 diabetes, proteinuria &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 900 mg/day and serum creatinine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, beta blockers, alpha blockers) to re</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ach a predefined blood pressure goal of &#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">22 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality was observed, while a positive trend in the reduction in ESRD and a significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduction in doubling of serum creatinine were observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subgroups which represented 32% and 26% of the overall study population respectively, a renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">benefit was not evident, although the confidence intervals do not exclude it. As for the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the overall population, although an increased incidence of non-fatal MI was seen for women and a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">failure was reduced in the overall population. However, no proper explanation for these findings in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">women has been identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The study of the &#x201c;Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diabetes Mellitus (IRMA 2)&#x201d; shows that irbesartan 300 mg delays progression to overt proteinuria in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(serum creatinine </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure goal was &#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg. Additional antihypertensive agents (excluding ACE </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improvement in the glomerular filtration rate (GFR) was not observed during the first three months of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment. The slowing in the progression to clinical proteinuria was evident as early as three months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and continued over the 2-years period. Regression to normoalbuminuria (&lt; 30 mg/day) was more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequent in the Karvea 300 mg group (34%) than in the placebo group (21%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to monotherapy was observed. Given their similar pharmacodynamic properties, these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease, cardiovascular disease, or both. The study was terminated early because of an increased risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">23 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren group than in the placebo group and adverse events and serious adverse events of interest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group than in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absorption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Distribution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The volume of distribution is 53-93 litres.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biotransformation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following oral or intravenous administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, 80-85% of the circulating plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(approximately 6%). </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> studies indicate that irbesartan is primarily oxidised by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Linearity/ non-linearity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are attained at 1.5-2 hours after oral administration. The total body and renal clearance are 157-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">176 and 3-3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11-15 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients. However, there was no difference in the half-life and accumulation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were also somewhat greater in older subjects </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years) than those of young subjects (18-40 years). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">However the terminal half-life was not significantly altered. No dosage adjustment is necessary in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elimination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, about 20% of the radioactivity is recovered in the urine, and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(twelve children over 12 years, nine children between 6 and 12 years). Results showed that C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, AUC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatic impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significantly altered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies have not been performed in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3</span></b><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-clinical safety </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies, high doses of irbesartan (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 250 mg/kg</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">/day in rats and &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 100 mg/kg/day in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At very high doses (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 500 mg/kg/day) degenerative changes in the kidney (such as interstitial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 90 mg/kg/day, in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 mg/kg/day). All of these changes were considered to be caused by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of mutagenicity, clastogenicity or carcinogenicity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility and reproductive performance were not affected in studies of male and female rats even at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is excreted in the milk of lactating rats. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abortion or early resorption were noted at doses causing significant maternal toxicity, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality. No teratogenic effects were observed in the rat or rabbit. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Microcrystalline cellulose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Croscarmellose sodium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lactose monohydrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium stearate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Colloidal hydrated silica </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregelatinized maize starch </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Poloxamer 188 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">25 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Do not store above 30&#xb0;C. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 14 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 28 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 98 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 x 1 tablet in PVC/PVDC/Aluminium perforated unit dose blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sanofi Winthrop Industrie </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">82 avenue Raspail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">94250 Gentilly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">France </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/004-006 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/011 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/014 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 27 August 1997 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of latest renewal: 27 August 2007 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency http://www.ema.europa.eu </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">26 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 300 mg tablets. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each tablet contains 300 mg of irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipient with known effect: 61.50 mg of lactose monohydrate per tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2773 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">engraved on the other side. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea is indicated in adults for the treatment of essential hypertension. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea at a dose of 150 mg once daily generally provides a better 24-hour blood pressure control than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialyzed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients and in the elderly over 75 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect with Karvea (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special Populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(75 mg) should be considered for patients undergoing haemodialysis (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">27 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical experience in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Older people</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">age, dosage adjustment is not usually necessary for older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">made. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of Administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For oral use. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Second and third trimesters of pregnancy (see sections 4.4 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Intravascular volume depletion: symptomatic hypotension, especially after the first dose, may occur in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment and kidney transplantation: when Karvea is used in patients with impaired renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">experience regarding the administration of Karvea in patients with a recent kidney transplantation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypertensive patients with type 2 diabetes and renal disease: the effects of irbesartan both on renal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with patients with advanced renal disease. In particular, they appeared less favourable in women and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-white subjects (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS): there is evidence that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual blockade therapy is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered absolutely necessary, this should only occur under specialist supervision and subject to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">28 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blockers should not be used concomitantly in patients with diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium in patients at risk is recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium: the combination of lithium and Karvea is not recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophic cardiomyopathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Primary aldosteronism: patients with primary aldosteronism generally will not respond to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therefore, the use of Karvea is not recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General: in patients whose vascular tone and renal function depend predominantly on the activity of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">underlying renal disease, including renal artery stenosis), treatment with angiotensin</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">converting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ischaemic cardiovascular disease could result in a myocardial infarction or stroke. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">possibly because of higher prevalence of low-renin states in the black hypertensive population (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">changed to alternative antihypertensive treatments which have an established safety profile for use in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16 years old but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the current data are insufficient to support an extension of the use in children until further data become </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available (see sections 4.8, 5.1 and 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipients: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 300 mg tablet contains lactose. Patients with rare hereditary problems of galactose intolerance, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">total lactase deficiency or glucose-galactose malabsorption should not take this medicine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 300 mg tablet contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tablet, that is to say essentially &#x2018;sodium-free&#x2019;. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diuretics and other antihypertensive agents: other antihypertensive agents may increase the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of irbesartan; however Karvea has been safely administered with other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">29 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotension when initiating therapy with Karvea (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aliskiren-containing products or ACE-inhibitors: clinical trial data has shown that dual blockade of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Potassium supplements and potassium-sparing diuretics:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based on experience with the use of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is, therefore, not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reversible increases in serum lithium concentrations and toxicity have been reported during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended.</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may occur. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased risk of worsening of renal function, including possible acute renal failure, and an increase in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium, especially in patients with poor pre-existing renal function. The combination should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be administered with caution, especially in the elderly. Patients should be adequately hydrated and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">consideration should be given to monitoring renal function after initiation of concomitant therapy, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">periodically thereafter. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Repaglinide: irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan increased the C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.3-fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">during the first trimester of pregnancy has not been conclusive; however a small increase in risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive treatments which have an established safety profile for use in pregnancy. When </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alternative therapy should be started. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Exposure to AIIRA therapy during the second and third trimesters is known to induce human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal function and skull is recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.3 and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended and alternative treatments with better established safety profiles during breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are preferable, especially while nursing a newborn or preterm infant. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is unknown whether irbesartan or its metabolites are excreted in human milk.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolites in milk (for details see 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the first signs of parental toxicity (see section 5.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">machine. When driving vehicles or operating machines, it should be taken into account that dizziness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or weariness may occur during treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose range), gender, age, race, or duration of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following table presents the adverse drug reactions that were reported in placebo-controlled trials </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chronic renal insufficiency and overt proteinuria and in excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The frequency of adverse reactions listed below is defined using the following convention: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">very common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/100 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); uncommon (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/1,000 to &lt; 1/100); rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are presented in order of decreasing seriousness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">31 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adverse reactions additionally reported from post&#x2013;marketing experience are also listed. These adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions are derived from spontaneous reports. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blood and lymphatic system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaemia, thrombocytopenia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immune system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaphylactic shock </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism and nutrition disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia, hypoglycaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nervous system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness, orthostatic dizziness* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vertigo, headache </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ear and labyrinth disorder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tinnitus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cardiac disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tachycardia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vascular disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">orthostatic hypotension* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">flushing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Respiratory, thoracic and mediastinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nausea/vomiting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea, dyspepsia/heartburn </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dysgeusia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatobiliary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">jaundice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis, abnormal liver function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skin and subcutaneous tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">leukocytoclastic vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Musculoskeletal and connective tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">musculoskeletal pain* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthralgia, myalgia (in some cases associated with increased plasma creatine kinase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">levels), muscle cramps </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal and urinary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> impaired renal function including cases of renal failure in patients at risk (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reproductive system and breast disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sexual dysfunction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">32 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General disorders and administration site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chest pain </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Investigations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with placebo. In diabetic hypertensive patients with microalbuminuria and normal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal function, hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 29.4% of the patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients with chronic renal insufficiency and overt proteinuria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 26.3% of the patients in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significant increases in plasma creatine kinase were commonly observed (1.7%) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan treated subjects. None of these increases were associated with identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical musculoskeletal events. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In 1.7% of hypertensive patients with advanced diabetic renal disease treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">child recipients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in Appendix V.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">also occur from overdose. No specific information is available on the treatment of overdose with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea. The patient should be closely monitored, and the treatment should be symptomatic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: Angiotensin-II antagonists, plain. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ATC code: C09C A04. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) antagonist. It is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected to block all actions of angiotensin-II mediated by the AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> receptor, regardless of the source </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) receptors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">33 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolic activation for its activity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical efficacy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose-related for once-a-day doses with a tendency towards plateau at doses above 300 mg. Doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses. Once daily dosing with 150 mg produced trough and mean 24-hour responses similar to twice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily dosing on the same total dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension has not been observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trough of 7-10/3-6 mm Hg (systolic/diastolic). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products that affect the renin-angiotensin system, black hypertensive patients have notably less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that of white patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no clinically important effect on serum uric acid or urinary uric acid secretion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension) children and adolescents aged 6 to 16 years over a three-week period. At the end of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose). No significant difference was apparent between these doses. Adjusted mean change of trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose), 5.6 mmHg (high dose). Over a subsequent two-week period where patients were re-randomized </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan (see section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension and type 2 diabetes with renal disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The &#x201c;Irbesartan Diabetic Nephropathy Trial (IDNT)&#x201d; shows that irbesartan decreases the progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,715 hypertensive patients with type </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 diabetes, proteinuria &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 900 mg/day and serum creatinine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">goal of &#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">34 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality was observed, while a positive trend in the reduction in ESRD and a significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduction in doubling of serum creatinine were observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subgroups which represented 32% and 26% of the overall study population respectively, a renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">benefit was not evident, although the confidence intervals do not exclude it. As for the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the overall population, although an increased incidence of non-fatal MI was seen for women and a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">failure was reduced in the overall population. However, no proper explanation for these findings in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">women has been identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The study of the &#x201c;Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diabetes Mellitus (IRMA 2)&#x201d; shows that irbesartan 300 mg delays progression to overt proteinuria in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(serum creatinine </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure goal was &#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg. Additional antihypertensive agents (excluding ACE </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improvement in the glomerular filtration rate (GFR) was not observed during the first three months of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment. The slowing in the progression to clinical proteinuria was evident as early as three months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and continued over the 2-years period. Regression to normoalbuminuria (&lt; 30 mg/day) was more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequent in the Karvea 300 mg group (34%) than in the placebo group (21%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combination with Ramipril Global Endpoint Trial) and NEPHRON-D (The Veterans Affairs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to monotherapy was observed. Given their similar pharmacodynamic properties, these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease, cardiovascular disease, or both. The study was terminated early because of an increased risk </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">35 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren group than in the placebo group and adverse events and serious adverse events of interest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group than in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absorption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Distribution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The volume of distribution is 53-93 litres.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biotransformation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following oral or intravenous administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, 80-85% of the circulating plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(approximately 6%). </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> studies indicate that irbesartan is primarily oxidised by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Linearity / non-linearity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are attained at 1.5-2 hours after oral administration. The total body and renal clearance are 157-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">176 and 3-3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11-15 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients. However, there was no difference in the half-life and accumulation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were also somewhat greater in older subjects </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years) than those of young subjects (18-40 years). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">However the terminal half-life was not significantly altered. No dosage adjustment is necessary in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elimination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, about 20% of the radioactivity is recovered in the urine, and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(twelve children over 12 years, nine children between 6 and 12 years). Results showed that C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, AUC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatic impairment: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significantly altered. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies have not been performed in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3</span></b><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-clinical safety </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies, high doses of irbesartan (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 250 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mg/kg/day in rats and &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 100 mg/kg/day in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At very high doses (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 500 mg/kg/day) degenerative changes in the kidney (such as interstitial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 90 mg/kg/day, in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 mg/kg/day). All of these changes were considered to be caused by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of mutagenicity, clastogenicity or carcinogenicity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility and reproductive performance were not affected in studies of male and female rats even at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is excreted in the milk of lactating rats. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abortion or early resorption were noted at doses causing significant maternal toxicity, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality. No teratogenic effects were observed in the rat or rabbit. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Microcrystalline cellulose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Croscarmellose sodium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lactose monohydrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium stearate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Colloidal hydrated silica </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregelatinized maize starch </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Poloxamer 188 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">37 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Do not store above 30&#xb0;C. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 14 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 28 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 98 tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 x 1 tablet in PVC/PVDC/Aluminium perforated unit dose blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sanofi Winthrop Industrie </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">82 avenue Raspail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">94250 Gentilly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">France </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/007-009 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/012 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/015 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 27 August 1997 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of latest renewal: 27 August 2007 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency http://www.ema.europa.eu </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">38 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 75 mg film-coated tablets. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each film-coated tablet contains 75 mg of irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipient with known effect: 25.50 mg of lactose monohydrate per film-coated tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Film-coated tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2871 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">engraved on the other side. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea is indicated in adults for the treatment of essential hypertension. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea at a dose of 150 mg once daily generally provides a better 24-hour blood pressure control than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialyzed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients and in the elderly over 75 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect with Karvea (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special Populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(75 mg) should be considered for patients undergoing haemodialysis (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">39 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical experience in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Older people</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">age, dosage adjustment is not usually necessary for older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available data are described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">made. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of Administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For oral use. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Second and third trimesters of pregnancy (see sections 4.4 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Intravascular volume depletion: symptomatic hypotension, especially after the first dose, may occur in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment and kidney transplantation: when Karvea is used in patients with impaired renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">experience regarding the administration of Karvea in patients with a recent kidney transplantation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypertensive patients with type 2 diabetes and renal disease: the effects of irbesartan both on renal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with patients with advanced renal disease. In particular, they appeared less favourable in women and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-white subjects (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS): there is evidence that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual blockade therapy is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered absolutely necessary, this should only occur under specialist supervision and subject to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blockers should not be used concomitantly in patients with diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium in patients at risk is recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium: the combination of lithium and Karvea is not recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophic cardiomyopathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Primary aldosteronism: patients with primary aldosteronism generally will not respond to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therefore, the use of Karvea is not recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General: in patients whose vascular tone and renal function depend predominantly on the activity of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">underlying renal disease, including renal artery stenosis), treatment with angiotensin</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">converting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ischaemic cardiovascular disease could result in a myocardial infarction or stroke. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">possibly because of higher prevalence of low-renin states in the black hypertensive population (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">changed to alternative antihypertensive treatments which have an established safety profile for use in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16 years old but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the current data are insufficient to support an extension of the use in children until further data become </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available (see sections 4.8, 5.1 and 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipients: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 75 mg film-coated tablet contains lactose. Patients with rare hereditary problems of galactose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 75 mg film-coated tablet contains sodium. This medicine contains less than 1 mmol sodium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(23 mg) per tablet, that is to say essentially &#x2018;sodium-free&#x2019;. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diuretics and other antihypertensive agents: other antihypertensive agents may increase the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of irbesartan; however Karvea has been safely administered with other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">41 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotension when initiating therapy with Karvea (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aliskiren-containing products or ACE-inhibitors: clinical trial data has shown that dual blockade of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Potassium supplements and potassium-sparing diuretics:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based on experience with the use of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is, therefore, not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reversible increases in serum lithium concentrations and toxicity have been reported during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may occur. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased risk of worsening of renal function, including possible acute renal failure, and an increase in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium, especially in patients with poor pre-existing renal function. The combination should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be administered with caution, especially in the elderly. Patients should be adequately hydrated and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">consideration should be given to monitoring renal function after initiation of concomitant therapy, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">periodically thereafter.</span><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Repaglinide: irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan increased the C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.3-fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">during the first trimester of pregnancy has not been conclusive; however a small increase in risk </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">42 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive treatments which have an established safety profile for use in pregnancy. When </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alternative therapy should be started. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Exposure to AIIRA therapy during the second and third trimesters is known to induce human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal function and skull is recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.3 and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended and alternative treatments with better established safety profiles during breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are preferable, especially while nursing a newborn or preterm infant. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is unknown whether irbesartan or its metabolites are excreted in human milk.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolites in milk (for details see 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the first signs of parental toxicity (see section 5.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">machines. When driving vehicles or operating machines, it should be taken into account that dizziness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or weariness may occur during treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose range), gender, age, race, or duration of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following table presents the adverse drug reactions that were reported in placebo-controlled trials </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chronic renal insufficiency and overt proteinuria and in excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The frequency of adverse reactions listed below is defined using the following convention: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">very common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/100 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); uncommon (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/1,000 to &lt; 1/100); rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are presented in order of decreasing seriousness. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">43 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adverse reactions additionally reported from post&#x2013;marketing experience are also listed. These adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions are derived from spontaneous reports. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blood and lymphatic system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaemia, thrombocytopenia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immune system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaphylactic shock </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism and nutrition disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia, hypoglycaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nervous system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness, orthostatic dizziness* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vertigo, headache </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ear and labyrinth disorder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tinnitus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cardiac disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tachycardia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vascular disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">orthostatic hypotension* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">flushing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Respiratory, thoracic and mediastinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nausea/vomiting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea, dyspepsia/heartburn </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dysgeusia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatobiliary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">jaundice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis, abnormal liver function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skin and subcutaneous tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">leukocytoclastic vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Musculoskeletal and connective tissue disorders  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">musculoskeletal pain* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthralgia, myalgia (in some cases associated with increased plasma creatine kinase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">levels), muscle cramps </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal and urinary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> impaired renal function including cases of renal failure in patients at risk (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reproductive system and breast disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sexual dysfunction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">44 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General disorders and administration site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chest pain </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Investigations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with placebo. In diabetic hypertensive patients with microalbuminuria and normal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal function, hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 29.4% of the patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients with chronic renal insufficiency and overt proteinuria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 26.3% of the patients in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significant increases in plasma creatine kinase were commonly observed (1.7%) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan treated subjects. None of these increases were associated with identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical musculoskeletal events. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In 1.7% of hypertensive patients with advanced diabetic renal disease treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">child recipients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in Appendix V.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">also occur from overdose. No specific information is available on the treatment of overdose with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea. The patient should be closely monitored, and the treatment should be symptomatic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: Angiotensin-II antagonists, plain. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ATC code: C09C A04. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) antagonist. It is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected to block all actions of angiotensin-II mediated by the AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> receptor, regardless of the source </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) receptors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">45 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolic activation for its activity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical efficacy</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose-related for once-a-day doses with a tendency towards plateau at doses above 300 mg. Doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses. Once daily dosing with 150 mg produced trough and mean 24-hour responses similar to twice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily dosing on the same total dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension has not been observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trough of 7-10/3-6 mm Hg (systolic/diastolic). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products that affect the renin-angiotensin system, black hypertensive patients have notably less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that of white patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no clinically important effect on serum uric acid or urinary uric acid secretion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension) children and adolescents aged 6 to 16 years over a three-week period. At the end of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose). No significant difference was apparent between these doses. Adjusted mean change of trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose), 5.6 mmHg (high dose). Over a subsequent two-week period where patients were re-randomized </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan (see section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension and type 2 diabetes with renal disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The &#x201c;Irbesartan Diabetic Nephropathy Trial (IDNT)&#x201d; shows that irbesartan decreases the progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,715 hypertensive patients with type </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">2 diabetes, proteinuria &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 900 mg/day and serum creatinine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal o</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">f &#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">46 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality was observed, while a positive trend in the reduction in ESRD and a significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduction in doubling of serum creatinine were observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subgroups which represented 32% and 26% of the overall study population respectively, a renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">benefit was not evident, although the confidence intervals do not exclude it. As for the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the overall population, although an increased incidence of non-fatal MI was seen for women and a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">failure was reduced in the overall population. However, no proper explanation for these findings in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">women has been identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The study of the &#x201c;Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diabetes Mellitus (IRMA 2)&#x201d; shows that irbesartan 300 mg delays progression to overt proteinuria in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(serum creatinine </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure goal was &#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg. Additional antihypertensive agents (excluding ACE </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improvement in the glomerular filtration rate (GFR) was not observed during the first three months of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment. The slowing in the progression to clinical proteinuria was evident as early as three months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and continued over the 2-years period. Regression to normoalbuminuria (&lt; 30 mg/day) was more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequent in the Karvea 300 mg group (34%) than in the placebo group (21%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to monotherapy was observed. Given their similar pharmacodynamic properties, these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">47 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease, cardiovascular disease, or both. The study was terminated early because of an increased risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren group that in the placebo group and adverse events and serious adverse events of interest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group than in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absorption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Distribution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The volume of distribution is 53 - 93 litres.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biotransformation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following oral or intravenous administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, 80-85% of the circulating plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(approximately 6%). </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> studies indicate that irbesartan is primarily oxidised by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Linearity/non-linearity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are attained at 1.5 - 2 hours after oral administration. The total body and renal clearance are 157 -</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 176 and 3 - 3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11 - 15 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients. However, there was no difference in the half-life and accumulation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were also somewhat greater in older </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years) than those of young subjects (18 - 40 years). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">However the terminal half-life was not significantly altered. No dosage adjustment is necessary in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elimination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, about 20% of the radioactivity is recovered in the urine, and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(twelve children over 12 years, nine children between 6 and 12 years). Results showed that C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, AUC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:767pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">48 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatic impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significantly altered.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies have not been performed in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3</span></b><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-c</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">linical safety studies, high doses of irbesartan (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 250 </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mg/kg/day in rats and &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 100 mg/kg/day in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At very high doses (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 500 mg/kg/day) degenerative changes in the kidney (such as interstitial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 90 mg/kg/day, in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 mg/kg/day). All of these changes were considered to be caused by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of mutagenicity, clastogenicity or carcinogenicity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility and reproductive performance were not affected in studies of male and female rats even at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is excreted in the milk of lactating rats. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abortion or early resorption were noted at doses causing significant maternal toxicity, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality. No teratogenic effects were observed in the rat or rabbit. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tablet core: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lactose monohydrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Microcrystalline cellulose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Croscarmellose sodium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypromellose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Silicon dioxide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium stearate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Film-coating: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lactose monohydrate </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">49 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypromellose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Titanium dioxide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Macrogol 3000 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Carnauba wax. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Do not store above 30&#xb0;C. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 14 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 28 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 30 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 84 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 90 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 98 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 x 1 film-coated tablet in PVC/PVDC/Aluminium perforated unit dose blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sanofi Winthrop Industrie </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">82 avenue Raspail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">94250 Gentilly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">France </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/016-020 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/031 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/034 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/037 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 27 August 1997 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of latest renewal: 27 August 2007 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency http://www.ema.europa.eu </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">51 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 150 mg film-coated tablets. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each film-coated tablet contains 150 mg of irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipient with known effect: 51.00 mg of lactose monohydrate per film-coated tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Film-coated tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2872 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">engraved on the other side. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea is indicated in adults for the treatment of essential hypertension. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea at a dose of 150 mg once daily generally provides a better 24-hour blood pressure control than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialyzed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients and in the elderly over 75 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect with Karvea (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special Populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(75 mg) should be considered for patients undergoing haemodialysis (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical experience in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Older people</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">age, dosage adjustment is not usually necessary for older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available data are described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">made. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of Administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For oral use. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Second and third trimesters of pregnancy (see sections 4.4 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Intravascular volume depletion: symptomatic hypotension, especially after the first dose, may occur in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment and kidney transplantation: when Karvea is used in patients with impaired renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">experience regarding the administration of Karvea in patients with a recent kidney transplantation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypertensive patients with type 2 diabetes and renal disease: the effects of irbesartan both on renal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with patients with advanced renal disease. In particular, they appeared less favourable in women and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-white subjects (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS): there is evidence that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual blockade therapy is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered absolutely necessary, this should only occur under specialist supervision and subject to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">53 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blockers should not be used concomitantly in patients with diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium in patients at risk is recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium: the combination of lithium and Karvea is not recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophic cardiomyopathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Primary aldosteronism: patients with primary aldosteronism generally will not respond to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therefore, the use of Karvea is not recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General: in patients whose vascular tone and renal function depend predominantly on the activity of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">underlying renal disease, including renal artery stenosis), treatment with angiotensin</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">converting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ischaemic cardiovascular disease could result in a myocardial infarction or stroke. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">possibly because of higher prevalence of low-renin states in the black hypertensive population (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">changed to alternative antihypertensive treatments which have an established safety profile for use in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16 years old but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the current data are insufficient to support an extension of the use in children until further data become </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available (see sections 4.8, 5.1 and 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipients: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 150 mg film-coated tablet contains lactose. Patients with rare hereditary problems of galactose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 150 mg fil -coated tablet contains sodium. This medicine contains less than 1 mmol sodium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(23 mg) per tablet, that is to say essentially &#x2018;sodium-free&#x2019;. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diuretics and other antihypertensive agents: other antihypertensive agents may increase the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of irbesartan; however Karvea has been safely administered with other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">54 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotension when initiating therapy with Karvea (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aliskiren-containing products or ACE-inhibitors: clinical trial data has shown that dual blockade of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Potassium supplements and potassium-sparing diuretics:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based on experience with the use of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is, therefore, not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reversible increases in serum lithium concentrations and toxicity have been reported during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may occur. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased risk of worsening of renal function, including possible acute renal failure, and an increase in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium, especially in patients with poor pre-existing renal function. The combination should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be administered with caution, especially in the elderly. Patients should be adequately hydrated and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">consideration should be given to monitoring renal function after initiation of concomitant therapy, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">periodically thereafter.</span><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Repaglinide: irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan increased the C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.3-fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:730pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">during the first trimester of pregnancy has not been conclusive; however a small increase in risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">55 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive treatments which have an established safety profile for use in pregnancy. When </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alternative therapy should be started. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Exposure to AIIRA therapy during the second and third trimesters is known to induce human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal function and skull is recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.3 and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended and alternative treatments with better established safety profiles during breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are preferable, especially while nursing a newborn or preterm infant. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is unknown whether irbesartan or its metabolites are excreted in human milk.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolites in milk (for details see 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the first signs of parental toxicity (see section 5.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">machines. When driving vehicles or operating machines, it should be taken into account that dizziness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or weariness may occur during treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose range), gender, age, race, or duration of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following table presents the adverse drug reactions that were reported in placebo-controlled trials </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chronic renal insufficiency and overt proteinuria and in excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The frequency of adverse reactions listed below is defined using the following convention: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">very common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/10); c</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ommon (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/100 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); uncommon (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/1,000 to &lt; 1/100); rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are presented in order of decreasing seriousness. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">56 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adverse reactions additionally reported from post&#x2013;marketing experience are also listed. These adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions are derived from spontaneous reports. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blood and lymphatic system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaemia, thrombocytopenia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immune system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaphylactic shock </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism and nutrition disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia, hypoglycaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nervous system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness, orthostatic dizziness* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vertigo, headache </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ear and labyrinth disorder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tinnitus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cardiac disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tachycardia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vascular disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">orthostatic hypotension* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">flushing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Respiratory, thoracic and mediastinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nausea/vomiting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea, dyspepsia/heartburn </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dysgeusia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatobiliary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">jaundice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis, abnormal liver function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skin and subcutaneous tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">leukocytoclastic vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Musculoskeletal and connective tissue disorders  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">musculoskeletal pain* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthralgia, myalgia (in some cases associated with increased plasma creatine kinase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">levels), muscle cramps </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal and urinary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impaired renal function including cases of renal failure in patients at risk (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reproductive system and breast disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sexual dysfunction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">57 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General disorders and administration site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chest pain </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Investigations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with placebo. In diabetic hypertensive patients with microalbuminuria and normal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal function, hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 29.4% of the patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients with chronic renal insufficiency and overt proteinuria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 26.3% of the patients in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significant increases in plasma creatine kinase were commonly observed (1.7%) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan treated subjects. None of these increases were associated with identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical musculoskeletal events. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In 1.7% of hypertensive patients with advanced diabetic renal disease treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">child recipients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in Appendix V.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">also occur from overdose. No specific information is available on the treatment of overdose with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea. The patient should be closely monitored, and the treatment should be symptomatic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: Angiotensin-II antagonists, plain. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ATC code: C09C A04. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) antagonist. It is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected to block all actions of angiotensin-II mediated by the AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> receptor, regardless of the source </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) receptors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">58 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolic activation for its activity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical efficacy</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose-related for once-a-day doses with a tendency towards plateau at doses above 300 mg. Doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses. Once daily dosing with 150 mg produced trough and mean 24-hour responses similar to twice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily dosing on the same total dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension has not been observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trough of 7-10/3-6 mm Hg (systolic/diastolic). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products that affect the renin-angiotensin system, black hypertensive patients have notably less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that of white patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no clinically important effect on serum uric acid or urinary uric acid secretion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension) children and adolescents aged 6 to 16 years over a three-week period. At the end of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose). No significant difference was apparent between these doses. Adjusted mean change of trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose), 5.6 mmHg (high dose). Over a subsequent two-week period where patients were re-randomized </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan (see section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension and type 2 diabetes with renal disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The &#x201c;Irbesartan Diabetic Nephropathy Trial (IDNT)&#x201d; shows that irbesartan decreases the progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,715 hypertensive patients with type 2 diabetes, prot</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">einuria &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 900 mg/day and serum creatinine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">59 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality was observed, while a positive trend in the reduction in ESRD and a significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduction in doubling of serum creatinine were observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subgroups which represented 32% and 26% of the overall study population respectively, a renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">benefit was not evident, although the confidence intervals do not exclude it. As for the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the overall population, although an increased incidence of non-fatal MI was seen for women and a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">failure was reduced in the overall population. However, no proper explanation for these findings in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">women has been identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The study of the &#x201c;Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diabetes Mellitus (IRMA 2)&#x201d; shows that irbesartan 300 mg delays progression to overt proteinuria in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(serum creatinine </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure goal was &#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg. Additional antihypertensive agents (excluding ACE </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improvement in the glomerular filtration rate (GFR) was not observed during the first three months of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment. The slowing in the progression to clinical proteinuria was evident as early as three months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and continued over the 2-years period. Regression to normoalbuminuria (&lt; 30 mg/day) was more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequent in the Karvea 300 mg group (34%) than in the placebo group (21%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to monotherapy was observed. Given their similar pharmacodynamic properties, these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">60 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease, cardiovascular disease, or both. The study was terminated early because of an increased risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren group than in the placebo group and adverse events and serious adverse events of interest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group than in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absorption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Distribution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The volume of distribution is 53 - 93 litres.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biotransformation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following oral or intravenous administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, 80-85% of the circulating plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(approximately 6%). </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> studies indicate that irbesartan is primarily oxidised by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Linearity / non-linearity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are attained at 1.5 - 2 hours after oral administration. The total body and renal clearance are 157 -</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 176 and 3 - 3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11 - 15 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients. However, there was no difference in the half-life and accumulation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were also somewhat greater in older </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years) than those of young subjects (18 - 40 years). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">However the terminal half-life was not significantly altered. No dosage adjustment is necessary in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elimination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, about 20% of the radioactivity is recovered in the urine, and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(twelve children over 12 years, nine children between 6 and 12 years). Results showed that C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, AUC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">61 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatic impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significantly altered.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies have not been performed in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3</span></b><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-clinical safety st</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">udies, high doses of irbesartan (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 250 mg/kg/day in rats </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 100 mg/kg/day in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At very high doses (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 500 mg/kg/day) degenerative changes in the kidney (such as interstitial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 90 mg/kg/day, in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 mg/kg/day). All of these changes were considered to be caused by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of mutagenicity, clastogenicity or carcinogenicity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility and reproductive performance were not affected in studies of male and female rats even at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is excreted in the milk of lactating rats. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abortion or early resorption were noted at doses causing significant maternal toxicity, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality. No teratogenic effects were observed in the rat or rabbit. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tablet core: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lactose monohydrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Microcrystalline cellulose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Croscarmellose sodium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypromellose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Silicon dioxide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium stearate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Film-coating: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lactose monohydrate </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">62 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypromellose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Titanium dioxide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Macrogol 3000 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Carnauba wax. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Do not store above 30&#xb0;C. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 14 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 28 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 30 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 84 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 90 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 98 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 x 1 film-coated tablet in PVC/PVDC/Aluminium perforated unit dose blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sanofi Winthrop Industrie </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">82 avenue Raspail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">94250 Gentilly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">France </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/021-025 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/032 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/035 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/038 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 27 August 1997 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of latest renewal: 27 August 2007 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">63 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency http://www.ema.europa.eu </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">64 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">1. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 300 mg film-coated tablets. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">2. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Each film-coated tablet contains 300 mg of irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipient with known effect: 102.00 mg of lactose monohydrate per film-coated tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">3. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Film-coated tablet. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2873 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">engraved on the other side. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">CLINICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea is indicated in adults for the treatment of essential hypertension. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Posology and method of administration </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Posology </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The usual recommended initial and maintenance dose is 150 mg once daily, with or without food. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea at a dose of 150 mg once daily generally provides a better 24-hour blood pressure control than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialyzed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients and in the elderly over 75 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effect with Karvea (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Special Populations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Renal impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with impaired renal function. A lower starting dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(75 mg) should be considered for patients undergoing haemodialysis (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">65 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hepatic impairment</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical experience in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Older people</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">age, dosage adjustment is not usually necessary for older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Paediatric population</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available data are described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">made. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Method of Administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">For oral use. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Second and third trimesters of pregnancy (see sections 4.4 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m</span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.5 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special warnings and precautions for use </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Intravascular volume depletion: symptomatic hypotension, especially after the first dose, may occur in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment and kidney transplantation: when Karvea is used in patients with impaired renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">experience regarding the administration of Karvea in patients with a recent kidney transplantation. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypertensive patients with type 2 diabetes and renal disease: the effects of irbesartan both on renal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with patients with advanced renal disease. In particular, they appeared less favourable in women and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-white subjects (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS): there is evidence that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual blockade therapy is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">considered absolutely necessary, this should only occur under specialist supervision and subject to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">66 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blockers should not be used concomitantly in patients with diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium in patients at risk is recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium: the combination of lithium and Karvea is not recommended (see section 4.5). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophic cardiomyopathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Primary aldosteronism: patients with primary aldosteronism generally will not respond to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Therefore, the use of Karvea is not recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General: in patients whose vascular tone and renal function depend predominantly on the activity of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">underlying renal disease, including renal artery stenosis), treatment with angiotensin</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">converting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ischaemic cardiovascular disease could result in a myocardial infarction or stroke. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">possibly because of higher prevalence of low-renin states in the black hypertensive population (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">changed to alternative antihypertensive treatments which have an established safety profile for use in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16 years old but </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the current data are insufficient to support an extension of the use in children until further data become </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">available (see sections 4.8, 5.1 and 5.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Excipients: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 300 mg film-coated tablet contains lactose. Patients with rare hereditary problems of galactose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea 300 mg film-coated tablet contains sodium. This medicine contains less than 1 mmol sodium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(23 mg) per tablet, that is to say essentially &#x2018;sodium-free&#x2019;. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diuretics and other antihypertensive agents: other antihypertensive agents may increase the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of irbesartan; however Karvea has been safely administered with other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">67 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotension when initiating therapy with Karvea (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Aliskiren-containing products or ACE-inhibitors: clinical trial data has shown that dual blockade of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Potassium supplements and potassium-sparing diuretics:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based on experience with the use of other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is, therefore, not recommended (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lithium:</span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reversible increases in serum lithium concentrations and toxicity have been reported during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have been very rarely reported with irbesartan so far. Therefore, this combination is not recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may occur. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">increased risk of worsening of renal function, including possible acute renal failure, and an increase in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">serum potassium, especially in patients with poor pre-existing renal function. The combination should </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">be administered with caution, especially in the elderly. Patients should be adequately hydrated and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">consideration should be given to monitoring renal function after initiation of concomitant therapy, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">periodically thereafter.</span><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Repaglinide: irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan increased the C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1.3-fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed when irbesartan was coadministered with warfarin, a medicinal product metabolised by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Fertility, pregnancy and lactation </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:743pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:755pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:768pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">during the first trimester of pregnancy has not been conclusive; however a small increase in risk </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">68 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">antihypertensive treatments which have an established safety profile for use in pregnancy. When </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">alternative therapy should be started. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Exposure to AIIRA therapy during the second and third trimesters is known to induce human </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal function and skull is recommended. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sections 4.3 and 4.4). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Because no information is available regarding the use of Karvea during breast-feeding, Karvea is not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended and alternative treatments with better established safety profiles during breast-feeding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are preferable, especially while nursing a newborn or preterm infant. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">It is unknown whether irbesartan or its metabolites are excreted in human milk.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolites in milk (for details see 5.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the first signs of parental toxicity (see section 5.3).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.7 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">machines. When driving vehicles or operating machines, it should be taken into account that dizziness </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or weariness may occur during treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.8 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Undesirable effects </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not differ between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose range), gender, age, race, or duration of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The following table presents the adverse drug reactions that were reported in placebo-controlled trials </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chronic renal insufficiency and overt proteinuria and in excess of placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The frequency of adverse reactions listed below is defined using the following convention: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">very c</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ommon (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); common (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/100 to &lt; </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1/10); uncommon (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/1,000 to &lt; 1/100); rare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are presented in order of decreasing seriousness. </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">69 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Adverse reactions additionally reported from post&#x2013;marketing experience are also listed. These adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reactions are derived from spontaneous reports. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Blood and lymphatic system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaemia, thrombocytopenia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Immune system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">anaphylactic shock </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Metabolism and nutrition disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known:  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia, hypoglycaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nervous system disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness, orthostatic dizziness* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">vertigo, headache </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Ear and labyrinth disorder </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tinnitus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cardiac disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">tachycardia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Vascular disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">orthostatic hypotension* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">flushing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Respiratory, thoracic and mediastinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Gastrointestinal disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nausea/vomiting </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diarrhoea, dyspepsia/heartburn </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dysgeusia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatobiliary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">jaundice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hepatitis, abnormal liver function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Skin and subcutaneous tissue disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">leukocytoclastic vasculitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Musculoskeletal and connective tissue disorders  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">musculoskeletal pain* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">arthralgia, myalgia (in some cases associated with increased plasma creatine kinase </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">levels), muscle cramps </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal and urinary disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not known: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> impaired renal function including cases of renal failure in patients at risk (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">section 4.4) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reproductive system and breast disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">sexual dysfunction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">General disorders and administration site conditions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">fatigue </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Uncommon: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">chest pain </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Investigations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Very common: Hyperkalaemia* occurred more often in diabetic patients treated with irbesartan than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">with placebo. In diabetic hypertensive patients with microalbuminuria and normal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal function, hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 29.4% of the patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients with chronic renal insufficiency and overt proteinuria, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hyperkalaemia (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 5.5 mEq/L) occurred in 46.3% of the patients in the irbesartan group </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and 26.3% of the patients in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Common: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significant increases in plasma creatine kinase were commonly observed (1.7%) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan treated subjects. None of these increases were associated with identifiable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical musculoskeletal events. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In 1.7% of hypertensive patients with advanced diabetic renal disease treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:142pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">child recipients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting of suspected adverse reactions  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">professionals are asked to report any suspected adverse reactions via the national reporting system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">listed in Appendix V.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">4.9 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Overdose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">also occur from overdose. No specific information is available on the treatment of overdose with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Karvea. The patient should be closely monitored, and the treatment should be symptomatic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacodynamic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Pharmacotherapeutic group: Angiotensin-II antagonists, plain. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ATC code: C09C A04. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Mechanism of action</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) antagonist. It is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">expected to block all actions of angiotensin-II mediated by the AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> receptor, regardless of the source </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">) receptors </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">71 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which generates </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not require </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">metabolic activation for its activity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Clinical efficacy</span><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose-related for once-a-day doses with a tendency towards plateau at doses above 300 mg. Doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">doses. Once daily dosing with 150 mg produced trough and mean 24-hour responses similar to twice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily dosing on the same total dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effect of Karvea is evident within 1-2 weeks, with the maximal effect </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension has not been observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">trough of 7-10/3-6 mm Hg (systolic/diastolic). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The efficacy of Karvea is not influenced by age or gender. As is the case with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">products that affect the renin-angiotensin system, black hypertensive patients have notably less </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">that of white patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There is no clinically important effect on serum uric acid or urinary uric acid secretion. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertension) children and adolescents aged 6 to 16 years over a three-week period. At the end of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose). No significant difference was apparent between these doses. Adjusted mean change of trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dose), 5.6 mmHg (high dose). Over a subsequent two-week period where patients were re-randomized </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan (see section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Hypertension and type 2 diabetes with renal disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The &#x201c;Irbesartan Diabetic Nephropathy Trial (IDNT)&#x201d; shows that irbesartan decreases the progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine and placebo. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">1,715 hypertensive patients with type 2 diabetes, prot</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">einuria &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 900 mg/day and serum creatinine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Karvea on the progression of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">72 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cause mortality was observed, while a positive trend in the reduction in ESRD and a significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">reduction in doubling of serum creatinine were observed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subgroups which represented 32% and 26% of the overall study population respectively, a renal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">benefit was not evident, although the confidence intervals do not exclude it. As for the secondary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the overall population, although an increased incidence of non-fatal MI was seen for women and a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">failure was reduced in the overall population. However, no proper explanation for these findings in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">women has been identified. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The study of the &#x201c;Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Diabetes Mellitus (IRMA 2)&#x201d; shows that irbesartan 300 mg delays progression to overt proteinuria in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(serum creatinine </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">&#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">effects (2 years) of Karvea on the progression to clinical (overt) proteinuria (urinary albumin excretion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">blood pressure goal was &#x2264;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 135/85 mmHg. Additional antihypertensive agents (excluding ACE </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">improvement in the glomerular filtration rate (GFR) was not observed during the first three months of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">treatment. The slowing in the progression to clinical proteinuria was evident as early as three months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and continued over the 2-years period. Regression to normoalbuminuria (&lt; 30 mg/day) was more </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">frequent in the Karvea 300 mg group (34%) than in the placebo group (21%). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Dual blockade of the renin-angiotensin-aldosterone system (RAAS) </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">compared to monotherapy was observed. Given their similar pharmacodynamic properties, these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">patients with diabetic nephropathy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">73 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">disease, cardiovascular disease, or both. The study was terminated early because of an increased risk </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">aliskiren group than in the placebo group and adverse events and serious adverse events of interest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">group than in the placebo group. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Pharmacokinetic properties </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Absorption </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">After oral administration, irbesartan is well absorbed: studies of absolute bioavailability gave values of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Distribution </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The volume of distribution is 53 - 93 litres.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Biotransformation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Following oral or intravenous administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, 80-85% of the circulating plasma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(approximately 6%). </span><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">In vitro</span></i><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> studies indicate that irbesartan is primarily oxidised by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Linearity / non-linearity </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">are attained at 1.5 - 2 hours after oral administration. The total body and renal clearance are 157 -</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 176 and 3 - 3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11 - 15 hours. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertensive patients. However, there was no difference in the half-life and accumulation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> values </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">were also somewhat greater in older </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">subjects (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 65 years) than those of young subjects (18 - 40 years). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">However the terminal half-life was not significantly altered. No dosage adjustment is necessary in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">older people. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Elimination </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">administration of </span><sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">14</span></sup><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">C irbesartan, about 20% of the radioactivity is recovered in the urine, and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Paediatric population </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:729pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:742pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">(twelve children over 12 years, nine children between 6 and 12 years). Results showed that C</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:6.96pt">max</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">, AUC </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:754pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">74 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">dosing. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Renal impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hepatic impairment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">significantly altered.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies have not been performed in patients with severe hepatic impairment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">5.3</span></b><b><i><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></i></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">non-</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">clinical safety studies, high doses of irbesartan (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 250 mg/kg/day in </span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">rats and &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 100 mg/kg/day in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">At very high doses (&#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 500 mg/kg/day) degenerative changes in the kidney (such as interstitial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 90 mg/kg/day, in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">macaques at &#x2265;</span><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> 10 mg/kg/day). All of these changes were considered to be caused by the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">pharmacological action of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hypertrophy of the renal juxtaglomerular cells does not appear to have any relevance. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">There was no evidence of mutagenicity, clastogenicity or carcinogenicity. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Fertility and reproductive performance were not affected in studies of male and female rats even at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">foetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Studies in animals indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Irbesartan is excreted in the milk of lactating rats. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">abortion or early resorption were noted at doses causing significant maternal toxicity, including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">mortality. No teratogenic effects were observed in the rat or rabbit. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.1 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Tablet core: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lactose monohydrate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Microcrystalline cellulose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Croscarmellose sodium </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypromellose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Silicon dioxide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Magnesium stearate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Film-coating: </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Lactose monohydrate </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Hypromellose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Titanium dioxide </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Macrogol 3000 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Carnauba wax. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.2 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not applicable. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.3 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">3 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.4 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Do not store above 30&#xb0;C. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.5 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Nature and contents of container </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 14 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 28 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 30 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 84 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 90 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 98 film-coated tablets in PVC/PVDC/Aluminium blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Cartons of 56 x 1 film-coated tablet in PVC/PVDC/Aluminium perforated unit dose blisters. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Not all pack sizes may be marketed. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">6.6 </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">Special precautions for disposal </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">requirements. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">7. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Sanofi Winthrop Industrie </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">82 avenue Raspail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">94250 Gentilly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">France </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">8. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/026-030 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/033 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/036 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">EU/1/97/049/039 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">9. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt"> </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:727pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of first authorisation: 27 August 1997 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:740pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Date of latest renewal: 27 August 2007 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:752pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:765pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>
<div id="page0" style="position:relative;width:595pt;height:841pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:70pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:796pt;left:293pt"><span style="font-family:ArialMT,sans-serif;font-size:8.04pt">76 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">10. </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:99pt"><b><span style="font-family:TimesNewRomanPS,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt">Agency http://www.ema.europa.eu </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRomanPSMT,serif;font-size:11.04pt"> </span></p>
</div>































































</body>
</html> 

